DaVita (NYSE: DVA) witnessed strong momentum year to date. Shares of the company rallied 34.5% compared with 11.2% growth of the industry in the same time frame. The S&P 500 Composite has risen 11.7% during the same period. With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment. Denver, CO-headquartered DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and in contracted hospitals across the United States. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. Image Source: Zacks Investment Research Catalysts Driving Growth The rally in the company's share price can be attributed to strength in its Dialysis and related lab services. The optimism, led by a solid first-quarter 2024 performance and robust business potential, is expected to contribute further. DaVita ended the first quarter of 2024 with better-than-expected results. The uptick in the company's overall top-line and bottom-line performances was encouraging. The opening of dialysis centers within the United States and acquiring centers overseas were promising. DaVita has narrowed its adjusted earnings per share outlook for 2024. The company expects adjusted EPS for 2024 in the range of $9.00-$9.80, which is narrowed from the previous expectations of ...